Evidence map›Paper›PMID 28148953›Full record

ArticleScientific reports2017

Retinopathy Signs Improved Prediction and Reclassification of Cardiovascular Disease Risk in Diabetes: A prospective cohort study.

Henrietta Ho, Carol Y Cheung, Charumathi Sabanayagam, Wanfen Yip, Mohammad Kamran Ikram, Peng Guan Ong, Paul Mitchell, Khuan Yew Chow, Ching Yu Cheng, E Shyong Tai and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Diabetic Retinopathy and Cardiovascular Disease: A Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Insights into Systemic Disease through Retinal Imaging-Based Oculomics.Translational vision science & technology · 2020
    Review
  17. Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2020
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Henrietta HoSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Carol Y CheungSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Charumathi SabanayagamSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Wanfen YipSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Mohammad Kamran IkramSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Peng Guan OngSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Paul MitchellCentre for Vision Research, University of Sydney, New South Wales 2006, Australia.
Khuan Yew ChowHealth Promotion Board, National Registry of Diseases Office, 168937, Singapore.
Ching Yu ChengSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
E Shyong TaiNational University Hospital Singapore, Division of Endocrinology, 119074, Singapore.
Tien Yin WongSingapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Medical School, 168751, Singapore.
Singapore National Eye Center · SGDuke-NUS Medical School · SGHealth Promotion Board · SGNational University Hospital · SGSingapore Eye Research Institute · SGUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CVD risk prediction in diabetics is imperfect, as risk models are derived mainly from the general population. We investigate whether the addition of retinopathy and retinal vascular caliber improve CVD prediction beyond established risk factors in persons with diabetes. We recruited participants from the Singapore Malay Eye Study (SiMES, 2004-2006) and Singapore Prospective Study Program (SP2, 2004-2007), diagnosed with diabetes but no known history of CVD at baseline. Retinopathy and retinal vascular (arteriolar and venular) caliber measurements were added to risk prediction models derived from Cox regression model that included established CVD risk factors and serum biomarkers in SiMES, and validated this internally and externally in SP2. We found that the addition of retinal parameters improved discrimination compared to the addition of biochemical markers of estimated glomerular filtration rate (eGFR) and high-sensitivity C-reactive protein (hsCRP). This was even better when the retinal parameters and biomarkers were used in combination (C statistic 0.721 to 0.774, p = 0.013), showing improved discrimination, and overall reclassification (NRI = 17.0%, p = 0.004). External validation was consistent (C-statistics from 0.763 to 0.813, p = 0.045; NRI = 19.11%, p = 0.036). Our findings show that in persons with diabetes, retinopathy and retinal microvascular parameters add significant incremental value in reclassifying CVD risk, beyond established risk factors.

Indexed as

BiomarkersCardiovascular DiseasesDiabetic RetinopathyFemaleHumansMaleMicrovesselsMiddle AgedProspective StudiesReproducibility of ResultsRetinal VesselsRisk FactorsBiomarkers

Identifiers

PMID28148953
PMCPMC5288652
OpenAlexW2585067770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.